Overview
99mTc-ABH2 SPECT/CT in Breast Cancer
Status:
Recruiting
Recruiting
Trial end date:
2024-01-30
2024-01-30
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
This prospective study will investigate the potential usefulness of 99mTc-ABH2 SPECT/CT in the diagnostic performance and evaluation efficacy of breast cancer.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Peking Union Medical College Hospital
Criteria
Inclusion Criteria:- clinically suspected primary breast cancer by mammography or ultrasonography and being
able to sign the written informed consent form
Exclusion Criteria:
- pregnancy or lactation, impaired liver or kidney failure, and undergoing any preceding
local or systemic therapies that might interfere HER2 binding